Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 13/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2324586 | 0.80 | CYP1A2 (0.41) | P2RX7P2RY14GAACYP1A2SMN1; SMN2 | |
| SCHEMBL1577128 | 0.79 | MAPT (0.51) | GAARAB9ACYP1A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL3817969 | 0.77 | CA12 (0.37) | GAARAB9ACYP1A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL13387689 | 0.71 | MAPT (0.44) | RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21963082 | 0.70 | NPC1 (0.49) | GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL3992683 | 0.69 | NPC1 (0.34) | GAARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL286598 | 0.69 | CA12 (0.42) | GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL18007580 | 0.68 | SMN1; SMN2 (0.71) | GAARAB9ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL286597 | 0.67 | CA12 (0.41) | GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL2884259 | 0.67 | MEN1 (0.55) | P2RY14GAARAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288403-B2 | Heterocyclic gamma secretase modulators | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2355817-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010052199-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120874-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120874-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | BACE1, APH1A, APP | P2RX7 2515/4885P2RY14 2700/4885GAA 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.